Charles Schwab’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Charles Schwab’s Portfolio PAND Stock Details PAND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-29,532	Closed	-$1.77M	–	3635
2021 Q1	$1.77M	Buy	29,532 +14,092	+91%	+$510K	﹤0.01%	2694
2020 Q4	$230K	Hold	15,440	–	–	﹤0.01%	3237
2020 Q3	$177K	Buy	+15,440	New	+$264K	﹤0.01%	3194

Charles Schwab's PAND Position: Q2 2021 in Review

Charles Schwab sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 29,532 shares — an estimated $1.77M sold.

Charles Schwab first reported a position in PAND in Q3 2020 and held it in 3 quarters. The position peaked at $1.77M in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

Charles Schwab reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Charles Schwab sold 29,532 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $1.77M.
Charles Schwab first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 3 quarters.
Charles Schwab's Pandion Therapeutics Inc. Common Stock position peaked at $1.77M in Q1 2021.
0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.